Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 29 n° 307

Chugai’s Bispecific Antibody “ERY974”

Posted by fidest press agency su sabato, 7 ottobre 2017

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase I clinical study for solid tumors, were published in the online edition of Science Translational Medicine on October 4, 2017. Glypican-3 (GPC3) is a membrane protein that is expressed with high frequency on the cellular membranes of various tumor cells including hepatocellular carcinoma, lung cancer, and gastric cancer. GPC3 is reported to be expressed in various tissues in the fetal stage and play an important role, but is rarely expressed in normal adult tissues. As GPC3 expression is observed through the malignant transformation of cells, GPC3 is thought to be a protein specific to cancer (tumor-associated antigen). ERY974 is a bispecific antibody that binds to both GPC3 on the cancer cell membrane and to CD3, a membrane protein expressed on T cells, a type of lymphocyte. ERY974 is a T cell Redirecting AntiBod(TRAB) created with Chugai’s proprietary antibody engineering technology, and while simultaneously binding to GPC3 and CD3 and directing T cells to cancer cells, it also activates T cells, specifically attacking and killing neighboring cancer cells. Based on this mechanism whereby it activates T cells and attacks cancer cells, TRAB is classified as a type of cancer immunotherapy.
According to the immunohistochemistry, GPC3 is expressed in various cancers (a hepatocellular carcinoma, a squamous lung cancer, a small cell lung cancer, an esophageal cancer, a gastric cancer and a head and neck cancer), and as previously reported, it is rarely expressed in normal tissues (30 different tissues) (in vitro) GPC3-dependent T cell activation and killing of cancer cells by ERY974 was observed in vitro In three different experimental tumor models using mouse, ERY974 demonstrated anti-tumor effects Anti-tumor effects were observed even in cancers where other cancer immunotherapies are ineffective (Mouse) Tolerability of ERY974 was observed in toxicity testing in animal Based on the results of this preclinical study, Chugai began phase I clinical trial of ERY974 in patients with GPC3 positive solid tumors in the United States in August 2016 (NCT02748837). As a leading company in the field of antibody therapeutics, Chugai will continue to contribute to global healthcare and the health of all people through the creation of innovative treatments using its proprietary antibody technologies.

Una Risposta to “Chugai’s Bispecific Antibody “ERY974””

  1. URL said

    … [Trackback]

    […] Read More: fidest.wordpress.com/2017/10/07/chugais-bispecific-antibody-ery974/ […]

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione / Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione / Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione / Modifica )

Google+ photo

Stai commentando usando il tuo account Google+. Chiudi sessione / Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: